Soleus Capital Management, L.P. - AMYLYX PHARMACEUTICALS INC ownership

AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 175 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.

Quarter-by-quarter ownership
Soleus Capital Management, L.P. ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$2,588,400
+39.6%
120,000
+89.8%
0.29%
+50.0%
Q1 2023$1,854,699
-0.9%
63,214
+24.8%
0.19%
-28.4%
Q4 2022$1,871,000
-84.5%
50,636
-88.2%
0.27%
-83.7%
Q3 2022$12,086,000429,3361.64%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,515,868$46,065,54315.30%
Alpha Wave Global, LP 853,262$15,623,2279.88%
Saturn V Capital Management LP 886,143$16,225,2786.79%
Ally Bridge Group (NY) LLC 272,690$4,992,9545.86%
Altium Capital Management LP 534,700$9,790,3575.11%
Boxer Capital, LLC 2,084,000$38,158,0402.03%
Octagon Capital Advisors LP 695,000$12,725,4501.96%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 295,000$5,398,5001.82%
Tri Locum Partners LP 282,862$5,179,2031.66%
Perceptive Advisors 2,688,873$49,233,2651.64%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders